Please wait while the formulary information is being retrieved.
BREXAFEMME (ibrexafungerp citrate)
- Recurrent Yeast Infection of Vagina and Surrounding Area
- yeast infection of vagina and vulva
150 mg tablet
- 2 tablets (300 mg) by oral route every 12 hours for 1 day
Default screening record
- 1 tablet (150 mg) by oral route every 12 hours for 1 day
- 2 tablets (300 mg) by oral route every 12 hours for 1 day
- None
Contraindicated
- None
Severe
Moderate
- None
- Pregnancy
Contraindicated
- None
Severe
Moderate
- None
BREXAFEMME (ibrexafungerp citrate)
- Recurrent Yeast Infection of Vagina and Surrounding Area
- yeast infection of vagina and vulva
- None
- Acute abdominal pain
- Diarrhea
- Dizziness
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Abnormal vaginal bleeding
- Back pain
- Dysmenorrhea
- Flatulence
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hypersensitivity drug reaction
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ibrexafungerp
Safety and effectiveness not established in pre-menarchal pediatric females.
- 1 Day – 13 Years
- Safety and effectiveness not established in pre-menarchal pediatric females.
Ibrexafungerp
- Severity Level:
1
- Additional Notes: Contraindicated during pregnancy
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ibrexafungerp
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication must not be used during pregnancy. It may harm an unborn baby. Your doctor should order a pregnancy test before starting this medication.<br /><br />Ask about reliable forms of birth control while using this medication and for 4 days after the last dose. If you are using this medication monthly, a pregnancy test should also be ordered before taking your monthly dose and birth control should be used during the 6-month treatment period and for 4 days after the last dose. If you become pregnant or think you may be pregnant, tell your doctor right away.
| Recurrent vulvovaginal candidiasis | |
| B37.3 | Candidiasis of vulva and vagina |
| B37.31 | Acute candidiasis of vulva and vagina |
| B37.32 | Chronic candidiasis of vulva and vagina |
| Vulvovaginal candidiasis | |
| B37.3 | Candidiasis of vulva and vagina |
| B37.31 | Acute candidiasis of vulva and vagina |
| B37.32 | Chronic candidiasis of vulva and vagina |
| 0-9 | A-Z |
|---|---|
| B37.3 | Candidiasis of vulva and vagina |
| B37.3 | Candidiasis of vulva and vagina |
| B37.31 | Acute candidiasis of vulva and vagina |
| B37.31 | Acute candidiasis of vulva and vagina |
| B37.32 | Chronic candidiasis of vulva and vagina |
| B37.32 | Chronic candidiasis of vulva and vagina |
Formulary Reference Tool